GE HealthCare Technologies Inc. reported results for 2026 with revenue of $5.3B and diluted EPS of $1.24, reflecting year-over-year revenue growth and higher profitability versus the prior-year period.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$5.3B$5.01B5.8% | Net income²$561M$486M15.4% | Diluted EPS³$1.24$1.0617% |
¹ Reported as “Total revenues”. ² Reported as “Net income attributable to GE HealthCare”. ³ Reported as “Diluted earnings per share attributable to GE HealthCare”.
Business Highlights
- Revenue growth was driven by strength in AIS and PDx, with total revenues up 6.6% year-to-date and organic growth of 3.2%.
- Company reorganized into AIS, PDx and PCS, with AIS formed by combining Imaging and AVS.
- Services expanded 7.6%; acquisitions of Intelerad and NMP were completed to bolster PDx and imaging offerings.
- PCS experienced fulfillment challenges and cost inflation, though tariff refunds provided material relief.
- Market momentum was led by CT, cardiovascular & interventional, molecular imaging, and contrast/radiopharma volume and pricing.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.